Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome
A Phase IIa, Proof of Concept, Randomized, Double-Blind, Dose-Finding, Cross-Over Study of the Efficacy, Safety and Tolerability of a New Enteric-Coated Cholestyramine Capsule in Adult Short Bowel Syndrome Patients
Sponsor: Pharmascience Inc.
Terminated
Difficult recruitment
Other Short Bowel Syndrome trials with similar outcome
This PHASE2 trial investigates Short Bowel Syndrome and is currently terminated or withdrawn. Pharmascience Inc. leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Mar 2022 — Sep 2022 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 7 earlier versions
-
Dec 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pharmascience Inc.
For direct contact, visit the study record on ClinicalTrials.gov .